PDF(Pubmed)
Abstract：
B cells have recently become a focus in breast cancer pathology due to their influence on tumour regression, prognosis, and response to treatment, besides their contribution to antigen presentation, immunoglobulin production, and regulation of adaptive responses. As our understanding of diverse B cell subsets in eliciting both pro- and anti-inflammatory responses in breast cancer patients increases, it has become pertinent to address the molecular and clinical relevance of these immune cell populations within the tumour microenvironment (TME). At the primary tumour site, B cells are either found spatially dispersed or aggregated in so-called tertiary lymphoid structures (TLS). In axillary lymph nodes (LNs), B cell populations, amongst a plethora of activities, undergo germinal centre reactions to ensure humoral immunity. With the recent approval for the addition of immunotherapeutic drugs as a treatment option in the early and metastatic settings for triple-negative breast cancer (TNBC) patients, B cell populations or TLS may resemble valuable biomarkers for immunotherapy responses in certain breast cancer subgroups. New technologies such as spatially defined sequencing techniques, multiplex imaging, and digital technologies have further deciphered the diversity of B cells and the morphological structures in which they appear in the tumour and LNs. Thus, in this review, we comprehensively summarise the current knowledge of B cells in breast cancer. In addition, we provide a user-friendly single-cell RNA-sequencing platform, called \"B singLe cEll rna-Seq browSer\" (BLESS) platform, with a focus on the B cells in breast cancer patients to interrogate the latest publicly available single-cell RNA-sequencing data collected from diverse breast cancer studies. Finally, we explore their clinical relevance as biomarkers or molecular targets for future interventions.
摘要：
由于B细胞对肿瘤消退的影响，最近已成为乳腺癌病理学的焦点。预后,以及对治疗的反应，除了它们对抗原呈递的贡献，免疫球蛋白生产，和适应性反应的调节。随着我们对不同B细胞亚群在乳腺癌患者中引发促炎和抗炎反应的理解增加，解决肿瘤微环境（TME）中这些免疫细胞群体的分子和临床相关性已变得相关。在原发肿瘤部位，发现B细胞在空间上分散或聚集在所谓的三级淋巴结构（TLS）中。在腋窝淋巴结（LN），B细胞群,在众多活动中，进行生发中心反应以确保体液免疫。随着最近批准在三阴性乳腺癌（TNBC）患者的早期和转移性环境中添加免疫治疗药物作为治疗选择，B细胞群或TLS可能类似于某些乳腺癌亚组中免疫疗法反应的有价值的生物标志物。新技术，如空间定义的测序技术，多路成像,和数字技术进一步破译了B细胞的多样性以及它们在肿瘤和LN中出现的形态结构。因此，在这次审查中,我们全面总结了乳腺癌B细胞的最新知识。此外,我们提供了一个用户友好的单细胞RNA测序平台，称为“BsingLecellrna-SeqbrowSer”（BLESS）平台，重点关注乳腺癌患者的B细胞，以询问从各种乳腺癌研究中收集的最新公开可用的单细胞RNA测序数据。最后,我们探讨了它们作为未来干预措施的生物标志物或分子靶标的临床相关性.
